Bladder Cancer - Results from #20

Proteomic analysis of non-muscle invasive and muscle invasive bladder cancer highlights distinct subgroups with metabolic, matrisomal, and immune hallmarks and emphasizes importance of the stromal compartment. November 27, 2024

French AFU Cancer Committee Guidelines - Update 2024-2026: Non-muscle invasive bladder cancer (NMIBC). November 26, 2024

French AFU Cancer Committee Guidelines - Update 2024-2026: Muscle-invasive bladder cancer (MIBC). November 26, 2024

State of the Art: The Microbiome in Bladder Cancer. November 26, 2024

Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Matched Cohort Studies. November 26, 2024

Penoscrotal Extension and Fistulation From Urothelial Carcinoma of the Bladder November 25, 2024

Comparative analysis of oncological outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer utilizing propensity score matching. November 25, 2024

Understanding the long-term impact of the COVID-19 pandemic on non-muscle-invasive bladder cancer outcomes: 12-Month follow-up data from the international, prospective COVIDSurg Cancer study. November 25, 2024

Uromonitor®: Clinical Validation and Performance Assessment of a Urinary Biomarker within the Surveillance of Non-Muscle Invasive Bladder Cancer Patients. November 22, 2024

Metastasis development in non-muscle-invasive bladder cancer. November 22, 2024

Efficacy and Safety of an Avelumab and Chemotherapy Combination Treatment Regimen in Cisplatin Ineligible Patients with Metastatic Urothelial Carcinoma - Expert Commentary November 21, 2024

A Novel Gene Expression Scoring System Predicts Recurrence in Non-Muscle-Invasive Bladder Cancer Patients. November 21, 2024

Artificial Intelligence can Facilitate Application of Risk Stratification Algorithms to Bladder Cancer Patient Case Scenarios. November 21, 2024

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months November 20, 2024

Performance and Clinical Implications of VI-RADS in detecting muscle invasion in bladder tumors: A prospective observational study. November 20, 2024

Spectral CT for non-invasive evaluation of bladder cancer grade. November 20, 2024

Guidelines versus real-world data in metastatic bladder cancer: A population-based study on first-line chemotherapy treatment patterns. November 19, 2024

Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group. November 19, 2024

The role of MRI in muscle-invasive bladder cancer: an update from the last two years. November 19, 2024

Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study. November 18, 2024

Page 2 of 522